Tenax Therapeutics TENX 深 沪
等待开盘 04-03 09:30:00 美东时间
15.015
-0.985
-6.16%
华盛通- 最 高15.90
- 今 开15.68
- 成交量 33.28万股
- 最 低 14.805
- 昨 收 16.00
- 总市值 2.58亿
- 52周最高 18.38
- 市盈率 静 --
- 换手率 1.94%
- 52周最低 4.63
- 委 比 60.38%
- 总股本 1719.76万
- 历史最高 274560.00
- 量 比 0.77
- 振 幅 6.84%
- 历史最低 4.63
- 每 手 1
- 风险率 3.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tenax Therapeutics Files Prospectus For Offering $300M Securities
https://www.sec.gov/Archives/edgar/data/34956/000165495426002661/tennx_s3.htm
03-24 23:44
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
Cantor Fitzgerald Initiates Coverage On Tenax Therapeutics with Overweight Rating, Announces Price Target of $35
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Overweight rating and announces Price Target of $35.
03-17 20:40
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
Tenax Therapeutics Q4 EPS $(0.38) Beats $(0.41) Estimate
Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.41) by 7.32 percent. This is a 111.11 percent decrease over losses of $(0.18) per share
03-10 19:18
Tenax Therapeutics Q4 net loss widens on higher R&D expenses
Tenax Therapeutics Q4 net loss widens on higher R&D expenses Overview U.S. pharmaceutical firm's Q4 net loss widened to $15.5 mln Company achieved randomization target in Phase 3 LEVEL study, topline data expected Q3 2026 Company initiated global Phase 3 LEVEL-2 trial and opened long-term OLE study
03-10 19:11
Tenax Therapeutics FY 2025 net loss rises 199% to USD 52.6 million
Tenax Therapeutics FY 2025 net loss rises 199% to USD 52.6 million Tenax reported a Q4 net loss of USD 15.54 million, up 148% from a year earlier. Q4 R&D expense rose 129% to USD 10.54 million, driven mainly by higher spending on the Phase 3 LEVEL trial and the global Phase 3 LEVEL-2 study, plus inc
03-10 19:04
BRIEF-Tenax Therapeutics Q4 Net Income USD -15.54 Million
BRIEF-Tenax Therapeutics Q4 Net Income USD -15.54 Million Mar 10 (Reuters) - Tenax Therapeutics Q4 operating expenses USD 16.449 million. Q4 operating income USD -16.449 million
03-10 19:00
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference
Tenax Therapeutics, a Phase 3 pharmaceutical company developing cardiopulmonary therapies, announced its participation in a fireside chat at the 2026 Leerink Partners Global Healthcare Conference in Miami, FL. The chat will feature Chris Giordano, Stuart Rich, M.D., and Douglas Randall on March 10, 2026, at 2:20 p.m. ET. A live or archived webcast will be available via the Company’s investor relations webpage. Tenax focuses on developing novel th...
03-03 12:00
美股牛股 | High Roller暴涨430%！联手Crypto布局预测市场；航天公司Sidus大涨逾20%
High Roller单日暴涨430%！联手Crypto布局预测市场产品；商业航天公司Sidus大涨逾20%，此前获美军SHIELD项目合同>>
01-15 16:04
